Aspire Biopharma Holdings Inc

Aspire Biopharma Holdings Inc(ASBP)股票分析

$8.510

+0.258 (+3.03%)收盘时

Loading chart…
High
8.700
Open
8.300
VWAP
8.43
Vol
21.48K
Mkt Cap
Low
8.070
Amount
181.02K
EV/EBITDA, TTM
0.00

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. The Company is a developer of multi-faceted patent-pending drug delivery technology. It is engaged in developing and marketing the disruptive technology for novel sublingual delivery mechanisms for known drugs. Its patent pending delivery system includes components formulated to allow sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract. Its delivery technology is focused on different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. Its Sublingual Aspirin Product addresses cardiology emergencies and pain management. Its other products include Melatonin, Vitamins, Erectile Dysfunction Medication, Caffeine Products, and Other Products, which includes anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide.

AI analysis of Aspire Biopharma Holdings Inc (ASBP)

hold

PowerUp Acquisition Corp is not a good buy right now due to its significant decline in value, with a year-to-date change of -94.82% and a one-year change of -98.77%. Although the recent 5-day change is +6.78%, the overall trend remains negative, and the RSI is at 73.071, indicating potential overbought conditions. The main risk is its current financial instability, highlighted by a negative net income of -1,268,142 USD in Q2 2026 and a gross margin of -47.68%.

估值指标

The current forward P/E ratio for Aspire Biopharma Holdings Inc (ASBP) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for ASBP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ASBP

$0.44

情景价格

B

Base

Base · 50%ASBP

$0.38

情景价格

B

Bear

Bear · 25%ASBP

$0.32

情景价格

Whales holding ASBP

V

VR Advisory Services Ltd.

+ HoldingASBP

-5.11%

3M Return

事件时间线

2026-08-10 (ET)

09:00:00

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems

2026-07-29 (ET)

12:30:00

Aspire Biopharma Holdings Inc Trading Halted

2026-07-20 (ET)

09:00:00

Aspire Biopharma Appoints Jarryd McNeil as BUZZ BOMB Sponsored Athlete

2026-06-12 (ET)

14:30:00

Aspire Biopharma Holdings Inc Trading Halted

09:00:00

Aspire Biopharma Acquires Dura Driver Control Systems for $30M

资讯

ASBP FAQ — answered by Alphio AI

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. The Company is a developer of multi-faceted patent-pending drug delivery technology. It is engaged in developing and marketing the disruptive technology for novel sublingual delivery mechanisms for known drugs. Its patent pending delivery system includes components formulated to allow sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract. Its delivery technology is focused on different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. Its Sublingual Aspirin Product addresses cardiology emergencies and pain management. Its other products include Melatonin, Vitamins, Erectile Dysfunction Medication, Caffeine Products, and Other Products, which includes anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide. It operates in the Healthcare sector.

PowerUp Acquisition Corp is not a good buy right now due to its significant decline in value, with a year-to-date change of -94.82% and a one-year change of -98.77%. Although the recent 5-day change is +6.78%, the overall trend remains negative, and the RSI is at 73.071, indicating potential overbought conditions. The main risk is its current financial instability, highlighted by a negative net income of -1,268,142 USD in Q2 2026 and a gross margin of -47.68%.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始